Biocode takes on global Long COVID crisis by sub-licensing novel diagnostic
Innovus, Stellenbosch University’s innovation and commercialisation division, is proud to announce that the University has patented a groundbreaking research method, which detects microclots in the blood of Long COVID patients. This IP has been licensed exclusively to the University start-up company, Biocode.
Biocode’s Managing Director and head of SU’s Department of Physiological Sciences, Prof Resia Pretorius, says between 10 and 30% of COVID-19 survivors worldwide have or had long-term effects after recovering from the acute COVID-19 infection. Common symptoms are constant fatigue, shortness of breath, brain fog, depression, and anxiety. The...